A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly ...

Over the past three decades, meaningful progress has been made in the research and understanding of cystic fibrosis (CF). 1 ...

A cell-penetrating nanobody repairs misfolded CFTR proteins in cystic fibrosis cell models, restoring function and boosting activity to near-normal levels when combined with existing therapies. The ...

Joint Press Release from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie and Charité - Universitätsmedizin Berlin ...

After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals ...

CFTR modulators, especially triple therapy, significantly improve sinonasal inflammation and nasal polyp size in patients with cystic fibrosis.

Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced the ...

Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...

This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance ...

Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder. Boehringer ...

Advanced non-viral gene delivery systems are expanding the range of indications and therapy modalities possible for the new generation of genetic medicines.